Artal Group S.A. held its stake in shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 150,000 shares of the biopharmaceutical company’s stock at the end of the 2nd quarter. Artal Group S.A. owned approximately 0.83% of Xenon Pharmaceuticals worth $473,000 as of its most recent SEC filing.
Several other large investors have also modified their holdings of XENE. K2 Principal Fund L.P. grew its position in shares of Xenon Pharmaceuticals by 104.4% during the 1st quarter. K2 Principal Fund L.P. now owns 116,975 shares of the biopharmaceutical company’s stock worth $468,000 after buying an additional 59,747 shares during the period. Renaissance Technologies LLC grew its position in shares of Xenon Pharmaceuticals by 90.1% during the 1st quarter. Renaissance Technologies LLC now owns 217,090 shares of the biopharmaceutical company’s stock worth $868,000 after buying an additional 102,890 shares during the period. KCG Holdings Inc. acquired a new stake in shares of Xenon Pharmaceuticals during the 1st quarter worth approximately $122,000. Sabby Management LLC acquired a new stake in shares of Xenon Pharmaceuticals during the 1st quarter worth approximately $1,186,000. Finally, Endurant Capital Management LP acquired a new stake in shares of Xenon Pharmaceuticals during the 1st quarter worth approximately $1,363,000. Institutional investors own 55.30% of the company’s stock.
Several equities research analysts have recently commented on XENE shares. Jefferies Group LLC lowered their price target on shares of Xenon Pharmaceuticals from $8.00 to $5.00 and set a “buy” rating for the company in a research report on Wednesday, June 28th. Canaccord Genuity reissued a “buy” rating and set a $5.00 price objective on shares of Xenon Pharmaceuticals in a research note on Tuesday, June 27th. Finally, Zacks Investment Research raised shares of Xenon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, July 1st. One investment analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $11.88.
Xenon Pharmaceuticals Inc. (NASDAQ:XENE) traded up 1.69% on Wednesday, reaching $3.00. 2,674 shares of the company traded hands. The stock’s market capitalization is $53.99 million. The firm has a 50 day moving average of $3.02 and a 200-day moving average of $4.07. Xenon Pharmaceuticals Inc. has a one year low of $2.25 and a one year high of $9.95.
Xenon Pharmaceuticals (NASDAQ:XENE) last posted its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.03). Xenon Pharmaceuticals had a negative return on equity of 47.53% and a negative net margin of 3,489.63%. The business had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.38 million. On average, analysts anticipate that Xenon Pharmaceuticals Inc. will post ($0.97) EPS for the current year.
In other news, major shareholder Bvf Partners L. P/Il bought 18,858 shares of the business’s stock in a transaction that occurred on Tuesday, August 15th. The shares were bought at an average cost of $2.41 per share, for a total transaction of $45,447.78. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Value Fund L. P. Biotechnology bought 85,461 shares of the business’s stock in a transaction that occurred on Tuesday, June 27th. The stock was purchased at an average price of $4.00 per share, for a total transaction of $341,844.00. The disclosure for this purchase can be found here. Over the last quarter, insiders purchased 306,611 shares of company stock worth $962,963. 9.40% of the stock is owned by company insiders.
TRADEMARK VIOLATION NOTICE: This piece was first posted by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was copied illegally and reposted in violation of United States & international trademark & copyright law. The original version of this piece can be accessed at https://www.chaffeybreeze.com/2017/09/20/artal-group-s-a-continues-to-hold-stake-in-xenon-pharmaceuticals-inc-xene.html.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company. It is engaged in discovering and developing a pipeline of differentiated therapeutics for orphan indications. Its product pipeline includes: Glybera, TV-45070, GDC-0310, XEN901 (Nav1.6 inhibitor) and XEN1101. Glybera is used for the treatment of lipoprotein lipase deficiency (LPLD).
Want to see what other hedge funds are holding XENE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xenon Pharmaceuticals Inc. (NASDAQ:XENE).
Receive News & Ratings for Xenon Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.